Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

Summary

This narrative review synthesises current evidence on anti-PD-1/PD-L1 and anti-CTLA-4 checkpoint inhibitor antibodies, which have demonstrated dramatic improvements in disease outcomes for melanoma patients and are now clinically approved internationally. The authors examine the immunological mechanisms underlying these therapies, their demonstrated efficacy, and critically assess their limitations, noting that the majority of advanced-stage melanoma patients do not respond or experience relapse. The review further explores emerging strategies to overcome resistance and extend the therapeutic utility of checkpoint inhibitors beyond melanoma to other cancer types.

UK applicability

These findings are relevant to UK oncology practice, as checkpoint inhibitors are approved and used within the NHS for melanoma and other cancers. The review's analysis of mechanism, efficacy and limitations would inform UK clinical decision-making and policy on immunotherapy provision, though the paper does not address UK-specific healthcare or commissioning contexts.

Key measures

Mechanisms of action of checkpoint inhibitors; clinical efficacy and disease outcomes; response rates and relapse patterns in advanced melanoma; limitations and resistance to therapy

Outcomes reported

The review examined the mechanisms of action, efficacy, and limitations of anti-PD-1/PD-L1 and anti-CTLA-4 checkpoint inhibitor antibodies in melanoma and other cancers. It explored clinical outcomes, resistance patterns, and future therapeutic avenues for these immunotherapies.

Topic tags